News

A January 2024 Forbes article highlights the crucial role firms like HEMEO play in optimizing the use of blood by clinicians. In the post-Covid era, when the number of people donating blood has decreased, innovative data-driven technologies like HEMEO offer ...

Dutch health tech startup HEMEO was selected as one of only ten innovative companies to participate in the ScaleNL, NBSO LA, Cedars-Sinai Accelerator program in Los Angeles, USA. This prestigious opportunity places HEMEO among a select group of firms poised ...

Since January 2024, HEMEO has had the great pleasure to welcome Leslie “Lee” DeGeer as its President and Chief Executive Officer. Lee is a seasoned medical device executive with more than 25 years of documented success in the Life Sciences ...

Hemeo announces the successful closure of its first equity finance round. Raising €675,000, it has been substantially oversubscribed, highlighting the strong interest raised by the potential of the Hemeo technology designed to revolutionise coagulation with data. We are honoured by ...

Over the past few months we have been contacted by several pharma and medtech companies interested to understand how our coagulation model could help them advance or accelerate their own research and development. We are happy to announce our first agreement ...

In 2020, Hemeo completed a first feasibility study supported by a grant from the SME Innovation Stimulation Topsectors (MIT) Noord-Holland. We are grateful for the support and delighted that Hemeo has now been awarded a second grant in support of a ...

We are pleased to share that Hemeo has been awarded an innovation loan by Rabobank. We are grateful to the Rabobank team in supporting our mission to “Revolutionise Coagulation with Data”. This loan enables us to develop our first application targeting ...

Hemeo is delighted to announce that it has signed a Collaborative Research Agreement with University of Florida Health. This agreement lays the ground for the sharing of targeted data and the research of optimal coagulation management for patients undergoing cardiac ...

Two publications have just been released, on Hemeo’s research: “Assessing the risk of DIC development in sepsis and SIRS” and “Real-world data on the effect of anticoagulants to prevent or treat DIC.” These publications are now available on our website, ...

We are proud to be part of this well known event and get the opportunity to share our story with a broader audience. We are gaining momentum across different communities, investors, clinicians, researchers. Europe is a great ecosystem for innovation ...

We are delighted to announce that Hemeo received seed funding from the Momentum fund. This 2.2M€ fund is designed to provide private investors the opportunity to invest in startups at an early stage while spreading the risk across a portfolio ...